The phase III international CheckMate 9ER trial continues to make headlines. Now published ahead of print in The Lancet Oncology…
featured news
The 12th Annual two-day WIN Symposium 2022, co-chaired by Richard L. Schilsky and our Director, Josep Tabernero, Chairman and Vice-Chairman…
The “J-BID – José Baselga Innovative Disruption Program” has an investment of up to 6 million euros and aims to…
For the first time in the context of brain metastasis, VHIO-led research has evidenced the striking preclinical efficacy of a…
HER2DX is the world’s first diagnostic test formulated specifically for HER2-positive (HER2+) breast cancer. HER2DX analyzes RNA on 27 genes…
For yet another year, researchers from the Vall d’Hebron Institute of Oncology (VHIO), which is part of the Vall d’Hebron…
